

L-methionine sulfoximine interacted with propofol and showed toxicity in PC12 cells

Ruicong Guan¹, Jing Chen^{Corresp., 1}, Fei Xiao¹, Yubo Xie^{Corresp. 1}

¹ Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China

Corresponding Authors: Jing Chen, Yubo Xie

Email address: 352880721@qq.com, xybdoctor@163.com

Background: L-Methionine sulfoximine (MSO) inhibits glutamine synthesis in a rodent animal model, and its limited clinical use is implicitly associated with glutamate deprivation and neurotoxicity. The purpose of this experiment was to determine the effect of MSO on pheochromocytoma (PC12) cells and its interaction with propofol-induced neuro-apoptosis. **Objective:** To study the effects of MSO on cell viability following 100 μ M propofol treatment and the impact of ribosomal S6 kinase 1 (RSK1) signaling on the PC12 cell line. **Methods:** PC12 cells were exposed to propofol-triggered neurotoxicity for 6 h and then subjected to MSO treatment. The gene and protein expression levels of members of the RSK1 signaling pathway were determined by real-time polymerase chain reaction, Western blot and histological analyses. The CCK8 test was used to assess cell viability, and cell proliferation and apoptosis were evaluated by flow cytometric analysis. **Results:** Propofol, a gamma-aminobutyric acid (GABA) agonist widely used in general anesthesia, significantly changed the expression level of cAMP response element-binding protein (CREB) and B cell lymphoma 2 (Bcl2) and solute carrier family 1 member 3 (Slc1a3), but not extracellular signal-regulated kinase 1/2 (ERK1/2). PC12 cells that were exposed to propofol for more than 6 h exhibited downregulation of RSK1. MSO aggravated the toxicity of propofol in PC12 cells via inhibition of the p90RSK1/CREB/Bcl2 signaling pathway.

L-Methionine sulfoximine interacted with propofol and showed toxicity in PC12 cells

Ruicong Guan¹, PhD; Jing Chen¹, PhD; Fei Xiao, MD; PhD; Yubo Xie^{1*} PhD

¹Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, China

*Corresponding author:

Prof. Yubo Xie

Department of Anesthesiology, The First Affiliated Hospital of

Guangxi Medical University, Nanning, 530021, China

Tel.: [±86-771-5356250](tel:+86-771-5356250); Fax: +86-771-5356250

E-mail: xybdoctor@163.com (Y. Xie).

The authors declared that they have no conflicts of interest related to this work.

Abstract

Background: L-Methionine sulfoximine (MSO) inhibits glutamine synthesis in a rodent animal model, and its limited clinical use is implicitly associated with glutamate deprivation and neurotoxicity. The purpose of this experiment was to determine the effect of MSO on pheochromocytoma (PC12) cells and its interaction with propofol-induced neuro-apoptosis.

Objective: To study the effects of MSO on cell viability following 100 μ M propofol treatment and the impact of ribosomal S6 kinase 1 (RSK1) signaling on the PC12 cell line.

Methods: PC12 cells were exposed to propofol-triggered neurotoxicity for 6 h and then subjected to MSO treatment. The gene and protein expression levels of members of the RSK1 signaling pathway were determined by real-time polymerase chain reaction, Western blot and histological analyses. The CCK8 test was used to assess cell viability, and cell proliferation and apoptosis were evaluated by flow cytometric analysis.

Results: Propofol, a gamma-aminobutyric acid (GABA) agonist widely used in general anesthesia, significantly changed the expression level of cAMP response element-binding protein (CREB) and B cell lymphoma 2 (Bcl2) and solute carrier family 1 member 3 (Slc1a3), but not extracellular signal-regulated kinase 1/2 (ERK1/2). PC12 cells that were exposed to propofol for more than 6 h exhibited downregulation of RSK1. MSO aggravated the toxicity of propofol in PC12 cells via inhibition of the p90RSK1/CREB/Bcl2 signaling pathway.

KEYWORDS

L-Methionine sulfoximine; propofol; cell viability; p90RSK1

Background:

Propofol is one of most widely used anesthetics in general anesthesia due to its short time action that easily controls the depth of sedation. Propofol impairs synapse plasticity combined with learning and memory loss, but the underlying mechanisms of its neuro-apoptotic effects are elusive (Cattano et al. 2008; Creeley et al. 2013; Karen et al. 2013; Yon et al. 2005; Zhong et al. 2018; Zhong et al. 2014). PC12 cells are neuron-like cells derived from a pheochromocytoma of the rat adrenal medulla and are utilized to study neuron signaling pathways such as Raf-mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) (Vaudry et al. 2002) due to their similar embryonic derivation.

L-Methionine sulfoximine (MSO), a characteristic regulator of glutamine metabolism, inhibits the activity of glutamine synthetase (GS) and glutamate cysteine ligase (Feary et al. 2017), potentiating both glutamate dehydrogenase and aspartate amino transferase, and is correlated with increased antibody productivity in cell lines. Notably, glutamine biosynthesis is catalyzed by GS, relevant to the metabolism of glutamate, NH_4^+ , and ATP (Kobayashi & Millhorn 2001). Subconvulsive doses of MSO reduces glutamine excitotoxicity from edema due to hepatic encephalopathy (Jeitner & Cooper 2014). GS inhibition has been shown to protect astrocytes from hyperammonemia for 24 h (Tanigami et al. 2005). However, the in vitro medium used in this study contained abundant glutamine, suggesting that the protective effect of MSO may have resulted from its isomer rather than the inhibition of GS (Peters et al. 2018). The concentrations of glutamate and glutamine must be maintained to prevent excitotoxicity, and a high dose of MSO has been shown to irreversibly inhibit GS activity (Phelps 1975). Propofol interacts with the neurotransmitter gamma-aminobutyric acid (GABA), which is widely expressed in the central nervous system. However, the mechanism accounting for propofol-triggered developmental neuro-apoptosis (Bosnjak et al. 2016) and the dose-dependent loss of consciousness remains unclear. In this study, we examined whether pretreatment with 5 μM MSO mitigated propofol-induced cell apoptosis and reversed the toxicity in propofol-treated PC12 cells by measuring the expression levels of proteins in the mitogen-activated protein kinase (MAPK) signal pathway.

Materials and Method:

Cell culture and treatment

Rat pheochromocytoma cells (PC12 cells) were purchased from the Chinese Academy of Sciences. Cells were seeded in a 25-cm² flask at a concentration of 1×10^5 cells/ml and cultured in Dulbecco's modified Eagle's medium (DMEM F-12; Gibco, Life Technologies, Grand Island NY). Media were supplemented with 10% fetal bovine serum (FBS, Gibco) and 1% penicillin-streptomycin solution (Gibco). Cells were incubated at 37°C under 5% CO_2 . L-Methionine

68 Sulfoximine (5 mM; Yuanye Biotechnology Co., Ltd., China) and propofol (100 μ M) were
69 dissolved in DMEM F-12 (Gibco)

70 CCK-8 assay

71 Cells were seeded in 96-well plates at a concentration of 1×10^5 cells/ml for adherence. The cells
72 were treated with MSO and/or propofol, and cell proliferation was measured using a CCK-8
73 Assay Kit (DOJINDO, Japan) according to the protocol.

74 Apoptosis assay

75 Following treatment with propofol for 4 h alone or in combination with 5 μ M MSO, intact and
76 treated cells were collected for staining with Annexin V-FITC/PI according to the instructions of
77 the apoptosis detection kit (#559763, BD Biosciences, China) using Cytomics FACSVerse (BD
78 Biosciences, USA).

79 RT-PCR

80 RT-PCR was performed using the following reagents and primers: GeneStar (2RT Reaction mix
81 & Script II RT MIX Lot #8BB01, gDNA Remover #A224-104; 2RealStar Green Fast Mixture
82 #A304-05), Bcl2l1 (GeneCopoeia, #RQPO47868), ribosomal S6 kinase 1 (RSK1; GeneCopoeia,
83 #RQP051014), cAMP response element-binding protein (CREB; forward 5' -
84 ACAGTTCAAGCCCAGCCACAG-3' and reverse 5' -GCACTAAGGTTACAGTGGGAGCAGA-3'),
85 Erk1/2 (forward 5' -GCGTTGGTACAGAGCTCCAGAA-3' and reverse 5' -
86 TGCAGCCCACAGACCAATATC-3'), glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
87 forward 5' -ACAGCAACAGGGTGGTGGAC-3' and reverse 5' -TTTGAGGGTGCAGCGAACTT-3').

88 Western blot

89 Cells were lysed with RIPA buffer supplemented with PMSF (100:1) on ice. As described by
90 Laemmli (Laemmli 1970), lysates were harvested and measured using a NanoDrop 2000. Then,
91 total protein was separated by gel electrophoresis and transferred to polyvinylidene difluoride
92 membranes (0.22- μ m pore size; EMD Millipore, Billerica, MA, USA). The membranes were
93 blocked with 5% BSA (Solarbio Life Science, Inc. China) for 2 h, incubated with a primary anti-
94 Bcl2 antibody (#40639, Signalway Antibody, USA), p90RSK (phospho-Thr348) antibody
95 (#11105, Signalway Antibody, USA), CREB antibody (#9197S Cell Signaling Technology, Inc.,
96 USA), and GAPDH antibody (#10494-1-AP, Proteintech, Inc., USA) at 4 $^{\circ}$ C overnight, followed
97 by incubation with a horseradish peroxidase-conjugated secondary antibody (1:10,000; LI-COR
98 Biosciences, Lincoln, USA).

99 Immunofluorescent staining and *immunohistochemical staining*

100 The cells were fixed with 4% formaldehyde for 20 min and washed 3 times with PBS before
101 every step at 37 $^{\circ}$ C, including permeabilization with 0.1% Triton X-100 (Solarbio Life Science,
102 Inc., China) for 5 min, blocking with 5% BSA for 10 min and incubation with p90RSK primary
103 antibodies (1:100; #11105, Signalway Antibody, USA) at 4 $^{\circ}$ C overnight. The cells were then
104 stained with a fluorescein-conjugated secondary antibody (1:100, Sigma-Aldrich, Germany) for
105 2 h. The *immunohistochemical staining* procedure followed the instructions in the SP-POD Kit
106 (Beijing Solarbio Science & Technology Co., Ltd., China). The images were acquired with an
107 Olympus BX53 microscope (Olympus Corporation, Tokyo, Japan), and the number of positive

cells and field area ratio were measured with Image-Pro Plus version 6.0 software (Media Cybernetics Inc., Rockville, MD, USA).

Statistical analysis

Data are presented as the mean \pm standard error and were analyzed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA) and GraphPad Prism 6 software (GraphPad Software Inc., La Jolla, CA, USA). Multiple comparisons were performed using one-way analysis of variance, followed by Dunnett's post hoc test, as appropriate. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

1. Effect of MSO on PC12 cells

Pretreatment with 5 μ M MSO induced cell toxicity in a time-dependent manner, as shown in Fig 1 ($F = 4.265$, $p = 0.028$).

3. Effect of MSO on propofol-treated PC12 cells

MSO had no protective effect on ERK1/2 expression but reduced the expression of P90RSK and CREB. Cells treated with MSO combined with propofol exhibited greater inactivation of cell proliferation and downregulation of Bcl2, CREB, expression (Fig 3, $F = 33.24$, $p < 0.001$) and more apoptosis than highly differentiated rat PC12 cells treated with propofol alone.

4. Expression of p90RSK1 in cultured PC12 cells

Immunofluorescent images of PC12 cells stained with a p90RSK1 monoclonal antibody revealed that MSO-treated PC12 cells expressed less p90RSK1 than untreated cells. Western blot analysis of p90RSK1 expression, as shown in Fig 2A ($F = 64.89$, $P < 0.001$; Fig 2B, $F = 79.24$, $P < 0.001$), revealed a lower density of the corresponding 90-kDa protein band in MSO-treated cells than in propofol-treated and normal cells, and RT-PCR analysis supported this finding. We also used flow cytometry to determine the apoptosis rates, as previously described. Activation of RSK1 prompts differentiation and outgrowth of neuron-like cells even in the absence of nerve growth factor (NGF) (Silverman et al. 2004).

MSO treatment had no effect on ERK1/2 expression but reduced the number of P90RSK-positive cells and consequently downregulated Bcl2 expression, mitigating cell apoptosis (Youle & Strasser 2008).

2. Effect of propofol on PC12 cells

Treatment with 100 μ M propofol significantly inhibited the cell viability of highly differentiated rat PC12 cells within 2 h and induced both apoptosis and death, as shown in Fig 4 ($F = 146.9$, $P < 0.001$). Propofol remarkably reduced the expression of Bcl2 but not

CREB. CREB is activated in response to MAPK, which exerts its proapoptotic effect by mitigating Bcl2 expression (Lonze & Ginty 2002).

Discussion

This study demonstrated that MAPK (RSK1) is highly expressed in PC12 cells but that this expression is downregulated by the administration of propofol. RSK1 has been shown to regulate CREB (Silverman et al.), and phosphorylated RSK1, CREB and Bcl2 have been shown to play a prominent role in cell growth (Subbalakshmi & Murthy 1983). Currently, there is a broad consensus implicating the RSK family in synaptic plasticity and memory formation. For example, mental retardation (Coffin-Lowry syndrome) is relevant to the human homolog RSK2 (Putz et al. 2004). Mounting evidence has shown that RSK1 potentiates cell proliferation by modulating glycogen synthase kinase (GSK)3 β , which in turn increases protein synthesis (Lin et al. 2010).

Excessive levels of neurotransmitters, including glutamate, glutamine, and GABA, can initiate programmed cell death. Interestingly, MSO inhibited neuron physiological activity and synaptic plasticity by lowering the concentration of both glutamate and glutamine in an animal model of amyotrophic lateral sclerosis (Ghoddoussi et al. 2010). In a recent study, we determined that the GABA agonist propofol induced hippocampal cell changes in Bax/Bcl2 levels (Lv et al. 2018). However, propofol at doses less than 50 μ M had no effect on viability in PC12 cells (Yang et al. 2019). Moreover, propofol at concentrations from 50 μ M to 1 mM reduced the potassium current amplitude in PC12 cells (Magnelli et al. 1992). Sedation with propofol at a dose of 10 μ g/ml has been reported to significantly decrease the expression of the Bcl2 protein, the key regulator of apoptosis (Adams et al. 2018), to a level that activates the mitochondrion intrinsic apoptotic pathway. Our previous reports showed that propofol downregulated neural proliferation and migration and induced apoptosis in vitro and in vivo (Wang et al. 2018; Zhong et al. 2014). During propofol infusion at 2 mg/kg/h, psychomotor functioning impairment and anterograde amnesia were observed (Zacny et al. 1992). As previously described, 100 μ M propofol is comparable to 10 μ g/ml blood concentration in humans (Cockshott 1985; Magnelli et al. 1992).

We established that inhibition of glutamine synthesis following administration of 5 mM MSO sensitized propofol-treated cellular processes through downregulation of RSK1, CREB and Bcl2 protein expression in PC12 cells.

Although MSO remarkably activates interleukin 6 and tumor necrosis factor alpha under conditions of lipopolysaccharide treatment (Peters et al. 2018), MSO is not a potent drug to prevent neuron death due to its effects on the accumulation of glycogen, which in turn can trigger convulsions. The anti-inflammatory effect of MSO might be relevant to two functional domains of RSK1, the N terminal kinase domain (part of the protein kinase A) and the C terminal kinase domain (part of calmodulin-dependent protein kinase [CaMK]), which are heavily involved in the activation of its downstream proteins, such as CREB and Bcl2 (Lin et al. 2019).

Finally, there were some important limitations of our study. For example, the activity of glutamate cysteine ligase and glutamine synthesis were not addressed in this study. Furthermore, we did not identify whether the inhibitory effect of MSO on gene expression could be ascribed to its isomers binding to signaling pathway receptors or inhibition of GS. In the future, we will continue to investigate toxic targets of MSO associated with solute carrier family 1 member 3 (Slc1a3).

Apoptosis, known as controlled cell death, along with neurodegeneration, has been well illustrated (Grilo & Mantalaris). Our findings suggest that the presence of late apoptotic cells was increased following propofol treatment (Yang et al. 2014). The mitogenic program has been reported to play a vital role in cell proliferation as well as survival. The neurotoxic effect of MSO is likely due to the direct interaction between glutamate receptors and the mitogenic gene RSK1 and the downstream effects on Bcl2. However, we did not measure glutamate receptors or chloride ion channels. MSO is known to affect cellular proliferation through its interactions with pro-apoptotic and anti-apoptotic proteins and, similar to propofol, causes a reduction in brain-derived neurotrophic factor (Chen et al. 2017). Our research suggests that MSO inhibits the p90RSK1-Bcl2-CREB signaling pathway, which in turn aggravates propofol-induced neuronal apoptosis.

Conflicts of interest

The authors have no conflicts of interest.

Acknowledgments

Yubo Xie made substantial contributions to the conception and design of the study. Ruicong Guan, PhD participated in the in vivo experiments. All authors read and approved the manuscript.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81373498 and 81060277), Science Study and Technology Development Program of Guangxi (No. 1355005-4-2), Science and Technology Research Project

208 of Guangxi University (No. 2013ZD014), and Guangxi Key Research and
209 Development Program (No. AB18221031).

210

211

212

- 213 Adams CM, Clark-Garvey S, Porcu P, and Eischen CM. 2018. Targeting the Bcl-2 Family in B Cell
214 Lymphoma. *Front Oncol* 8:636. 10.3389/fonc.2018.00636
- 215 Bosnjak ZJ, Logan S, Liu Y, and Bai X. 2016. Recent Insights Into Molecular Mechanisms of
216 Propofol-Induced Developmental Neurotoxicity: Implications for the Protective Strategies.
217 *Anesth Analg* 123:1286-1296. 10.1213/ANE.0000000000001544
- 218 Cattano D, Young C, Straiko MM, and Olney JW. 2008. Subanesthetic doses of propofol induce
219 neuroapoptosis in the infant mouse brain. *Anesth Analg* 106:1712-1714.
220 10.1213/ane.0b013e318172ba0a
- 221 Chen SD, Wu CL, Hwang WC, and Yang DI. 2017. More Insight into BDNF against
222 Neurodegeneration: Anti-Apoptosis, Anti-Oxidation, and Suppression of Autophagy. *Int J*
223 *Mol Sci* 18. 10.3390/ijms18030545
- 224 Cockshott ID. 1985. Propofol ('Diprivan') pharmacokinetics and metabolism--an overview.
225 *Postgraduate Medical Journal* 61 Suppl 3:45.
- 226 Creeley C, Dikranian K, Dissen G, Martin L, Olney J, and Brambrink A. 2013. Propofol-induced
227 apoptosis of neurones and oligodendrocytes in fetal and neonatal rhesus macaque brain.
228 *Br J Anaesth* 110 Suppl 1:i29-38. 10.1093/bja/aet173
- 229 Feary M, Racher AJ, Young RJ, and Smales CM. 2017. Methionine Sulfoximine Supplementation
230 Enhances Productivity in GS-CHOK1SV Cell Lines Through Glutathione Biosynthesis.
231 *Biotechnology Progress* 33:17-25. 10.1002/btpr.2372
- 232 Ghoddoussi F, Galloway MP, Jambekar A, Bame M, Needleman R, and Brusilow WSA. 2010.
233 Methionine sulfoximine, an inhibitor of glutamine synthetase, lowers brain glutamine and
234 glutamate in a mouse model of ALS. *J Neurol Sci* 290:41-47.
- 235 Grilo AL, and Mantalaris A. Apoptosis: A mammalian cell bioprocessing perspective. LID -
236 S0734-9750(19)30031-X [pii] LID - 10.1016/j.biotechadv.2019.02.012 [doi].
- 237 Jeitner TM, and Cooper AJL. 2014. Inhibition of human glutamine synthetase by L-methionine-
238 S,R-sulfoximine-relevance to the treatment of neurological diseases. *Metab Brain Dis*
239 29:983-989.
- 240 Karen T, Schlager GW, Bendix I, Sifringer M, Herrmann R, Pantazis C, Enot D, Keller M, Kerner
241 T, and Felderhoff-Mueser U. 2013. Effect of propofol in the immature rat brain on short-
242 and long-term neurodevelopmental outcome. *PLoS One* 8:e64480.
243 10.1371/journal.pone.0064480
- 244 Kobayashi S, and Millhorn DE. 2001. Hypoxia regulates glutamate metabolism and membrane
245 transport in rat PC12 cells. *J Neurochem* 76:1935-1948.
- 246 Laemmli UK. 1970. Cleavage of structural proteins during the assembly of the head of
247 bacteriophage T4. *Nature*.

- Lin L, Bu G, Mars WM, Reeves WB, Tanaka S, and Hu K. 2010. tPA activates LDL receptor-related protein 1-mediated mitogenic signaling involving the p90RSK and GSK3beta pathway. *Am J Pathol* 177:1687-1696. 10.2353/ajpath.2010.100213
- Lin L, White SA, and Hu K. 2019. Role of p90RSK in Kidney and Other Diseases. *Int J Mol Sci* 20. 10.3390/ijms20040972
- Lonze BE, and Ginty DD. 2002. Function and Regulation of CREB Family Transcription Factors in the Nervous System. *Neuron* 35:605-623. [https://doi.org/10.1016/S0896-6273\(02\)00828-0](https://doi.org/10.1016/S0896-6273(02)00828-0)
- Lv J, Liang Y, Tu Y, Chen J, and Xie Y. 2018. Hypoxic preconditioning reduces propofol-induced neuroapoptosis via regulation of Bcl-2 and Bax and downregulation of activated caspase-3 in the hippocampus of neonatal rats. *Neurol Res*:1-7. 10.1080/01616412.2018.1477545
- Magnelli V, Nobile M, and Maestroni E. 1992. K+ channels in PC12 cells are affected by propofol. *Pflugers Arch* 420:393-398.
- Peters TJ, Jambekar AA, and Brusilow WSA. 2018. In vitro suppression of inflammatory cytokine response by methionine sulfoximine. *Journal of Inflammation-London* 15. ARTN 17 10.1186/s12950-018-0193-8
- Phelps CH. 1975. An ultrastructural study of methionine sulfoximine-induced glycogen accumulation in astrocytes of the mouse cerebral cortex. *J Neurocytol* 4:479-490.
- Putz G, Bertolucci F, Raabe T, Zars T, and Heisenberg M. 2004. The S6KII (rsk) gene of *Drosophila melanogaster* differentially affects an operant and a classical learning task. *Journal of Neuroscience* 24:9745-9751. 10.1523/JNEUROSCI.3211-04.2004
- Silverman E, Frodin M Fau - Gammeltoft S, Gammeltoft S Fau - Maller JL, and Maller JL. Activation of p90 Rsk1 is sufficient for differentiation of PC12 cells.
- Silverman E, Frodin M, Gammeltoft S, and Maller JL. 2004. Activation of p90(Rsk1) is sufficient for differentiation of PC12 cells. *Molecular and Cellular Biology* 24:10573-10583. 10.1128/Mcb.24.24.10573-10583.2004
- Subbalakshmi GY, and Murthy CR. 1983. Effects of methionine sulfoximine on the enzymes of glutamate metabolism in isolated astrocytes of rat brain. *Biochem Pharmacol* 32:3695-3700.
- Tanigami H, Rebel A, Martin LJ, Chen TY, Brusilow SW, Traystman RJ, and Koehler RC. 2005. Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats. *Neuroscience* 131:437-449. 10.1016/j.neuroscience.2004.10.045
- Vaudry D, Stork PJ, Lazarovici P, and Eiden LE. 2002. Signaling pathways for PC12 cell differentiation: making the right connections. *Science* 296:1648-1649. 10.1126/science.1071552
- Wang H, Zhang S, Zhang A, and Yan C. 2018. Propofol Prevents the Progression of Malignant Pheochromocytoma In Vitro and In Vivo. *DNA Cell Biol* 37:308-315. 10.1089/dna.2017.3972
- Yang B, Liang G, Khojasteh S, Wu Z, Yang W, Joseph D, and Wei H. 2014. Comparison of neurodegeneration and cognitive impairment in neonatal mice exposed to propofol or isoflurane. *PLoS One* 9:e99171.
- Yang M, Wang Y, Liang G, Xu Z, Chu CT, and Wei H. 2019. Alzheimer's Disease Presenilin-1 Mutation Sensitizes Neurons to Impaired Autophagy Flux and Propofol Neurotoxicity: Role of Calcium Dysregulation. *J Alzheimers Dis* 67:137-147. 10.3233/jad-180858

- Yon JH, Daniel-Johnson J, Carter LB, and Jevtovic-Todorovic V. 2005. Anesthesia induces neuronal cell death in the developing rat brain via the intrinsic and extrinsic apoptotic pathways. *Neuroscience* 135:815-827. 10.1016/j.neuroscience.2005.03.064
- Youle RJ, and Strasser A. 2008. The BCL-2 protein family: opposing activities that mediate cell death. *Nature Reviews Molecular Cell Biology* 9:47. 10.1038/nrm2308
- <https://www.nature.com/articles/nrm2308#supplementary-information>
- Zacny JP, Lichtor JL, Coalson DW, Finn RS, Uitvlugt AM, Glosten B, Flemming DC, and Apfelbaum JL. 1992. Subjective and psychomotor effects of subanesthetic doses of propofol in healthy volunteers. *Anesthesiology* 76:696-702.
- Zhong Y, Chen J, Li L, Qin Y, Wei Y, Pan S, Jiang Y, Chen J, and Xie Y. 2018. PKA-CREB-BDNF signaling pathway mediates propofol-induced long-term learning and memory impairment in hippocampus of rats. *Brain Res* 1691:64-74. 10.1016/j.brainres.2018.04.022
- Zhong Y, Liang Y, Chen J, Li L, Qin Y, Guan E, He D, Wei Y, Xie Y, and Xiao Q. 2014. Propofol inhibits proliferation and induces neuroapoptosis of hippocampal neurons in vitro via downregulation of NF-kappaB p65 and Bcl-2 and upregulation of caspase-3. *Cell Biochem Funct* 32:720-729. 10.1002/cbf.3077

318

319 Figure 1. A high dose of propofol induced neurotoxicity in a time-dependent manner. Treatment
320 with 5 μ M MSO demonstrated no neuroprotection. Cell viability was further determined by
321 CCK8. Cell viability was significantly decreased in the MSO plus propofol group. * $p < 0.05$ and
322 ** $p < 0.01$ vs control; # $P < 0.05$ vs the propofol group.

323 Figure 2. Propofol decreased Bcl2 and CREB expression but had no effect on Scl1a3 expression.
324 MSO significantly decreased Scl1a3 gene expression (J). MSO had no protective effect against
325 exposure to a high dose of propofol and inactivation of the p90RSK1-Bcl2-CREB pathway.

326 RT-PCR and Western blotting analyses were performed to detect the expression of p90RSK1,
327 ERK1/2, Bcl2, CREB, and GAPDH at the protein (A-E) and mRNA (F -J) levels. * $p < 0.05$ and
328 ** $p < 0.01$ vs control; # $P < 0.05$ vs the propofol group.

329 Figure 3. MSO exposure for 4 h decreased RSK1 marker intensity in vitro. A dendritic segment
330 was picked according to RSK1 staining from each cell, and the locations for images taken were
331 defined as 20 μ m from the nucleus identified by DAPI staining. Normal PC12 cells showed
332 stronger red fluorescent intensity than cells treated with propofol or MSO, suggesting that
333 p90RSK1 plays a vital role in cellular processes. Pretreatment with MSO led to weaker red
334 fluorescence in cells treated with propofol. $F = 73.88$ * $p < 0.05$ and ** $p < 0.01$ vs control;
335 # $P < 0.05$ vs the propofol group. (n=50 neurons measured per group) Bars: 20 μ m.

336 Figure 4. MSO combined with propofol significantly increased the apoptotic rates compared with
337 propofol alone (one-way ANOVA, $F = 146.9$; # $p < 0.001$, n=3).

338

339

340

341

342

343

344

Figure 1(on next page)

cell viability

A high dose of propofol induced neurotoxicity in a time-dependent manner. Treatment with 5 μ M MSO demonstrated no neuroprotection. Cell viability was further determined by CCK8. Cell viability was significantly decreased in the MSO plus propofol group. * $p < 0.05$ and ** $p < 0.01$ vs control; # $P < 0.05$ vs the propofol group.




Figure 2 (on next page)

Western blotting analyses were performed to detect the expression of p90RSK1, ERK1/2, Bcl2, CREB, and GAPDH at the protein (A-E)

Propofol decreased Bcl2 and CREB expression but had no effect on Scl1a3 expression.

A

Control

Propofol

MSO+P

MSO


PeerJ

Preprints


NOT PEER-REVIEWED




B



C



D



E





Figure 3(on next page)


the expression of p90RSK1, ERK1/2, Bcl2, CREB, and GAPDH at the mRNA (F -J) levels.

MSO significantly decreased Scl1a3 gene expression


F




G



H



I



J





Figure 4(on next page)

Immuno-fluorescence of PC12

MSO exposure for 4 h decreased RSK1 marker intensity in vitro. A dendritic segment was picked according to RSK1 staining from each cell, and the locations for images taken were defined as 20 μm from the nucleus identified by DAPI staining. Normal PC12 cells showed stronger red fluorescent intensity than cells treated with propofol or MSO, suggesting that p90RSK1 plays a vital role in cellular processes. Pretreatment with MSO led to weaker red fluorescence in cells treated with propofol. $F=73.88$ * $p<0.05$ and ** $p<0.01$ vs control; # $P<0.05$ vs the propofol group. (n=50 neurons measured per group) Bars: 20 μm .

A



B





Figure 5 (on next page)

The apoptotic rates of PC12

MSO combined with propofol significantly increased the apoptotic rates compared with propofol alone (one-way ANOVA, $F=146.9$; $\#p<0.001$, $n=3$).

A



B

